Al­ny­lam’s John Maraganore isn’t the on­ly CEO to leave his post; CRISPR’s chief com­mer­cial of­fi­cer takes the helm at a pro­tein degra­da­tion play­er

The de­par­ture of a num­ber of CEOs is the pre­vail­ing theme that kicks off this week’s in­stall­ment: In a stun­ner, Al­ny­lam CEO John Maraganore an­nounced that Yvonne Green­street will be his suc­ces­sor at the end of the year. Maraganore, the Cam­bridge, MA biotech’s found­ing chief ex­ec­u­tive since 2002 who has helped in­vig­o­rate the RNAi space, will step in­to a con­sult­ing role un­til March 31 and main­tain his pres­ence in the com­pa­ny as a mem­ber of the sci­en­tif­ic ad­vi­so­ry board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER